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At a glance commentary: 
Scientific Knowledge on the Subject.  Our understanding of the effects of anti-staphylococcal 
antibiotic prophylaxis is limited to 4 randomised trials examining the utility of various 
antibiotics.  In one study more children in the treatment group isolated Pseudomonas 
aeruginosa. 
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What This Study Adds to the Field.  This registry study describes the ‘real world’ first detection 
of S. aureus and P. aeruginosa in the UK (where antibiotic prophylaxis is recommended), and 
US (where it is not used), and provides additional data regarding the benefits and risks of S. 
aureus prophylaxis in young children with CF.  Risks of first detection of S. aureus and P. 
aeruginosa are greater in the US than the UK. In the UK, risk of first detection of S. aureus is 
not reduced among those receiving flucloxacillin prophylaxis, while the risk of first detection 
of P. aeruginosa is more than twice as great among those receiving flucloxacillin prophylaxis 
than among those receiving no prophylaxis. 
Online supplement.  This article has an online data supplement, which is accessible from this 
issue’s table of content online at www. atsjournals.org 
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ABSTRACT 
Rationale 
Consensus is lacking regarding anti-staphylococcal antibiotic prophylaxis use for young 
children with cystic fibrosis.  Prophylaxis is recommended in the UK, but recommended 
against in the US.   
Objectives 
To test the hypothesis that anti-staphylococcal antibiotic prophylaxis is associated with a 
decreased risk of Staphylococcus aureus acquisition, but no increased risk of Pseudomonas 
aeruginosa acquisition. 
Methods 
We undertook a longitudinal observational study of children with cystic fibrosis who were 
recruited from birth (or their first registry entry in the period) and followed until the age of 4 
years (1500 days) using UK CF Trust and US CF Foundation Registries, 2000-2009. Children 
were excluded if they had a culture positive for S.aureus or P.aeruginosa, or were receiving 
inhaled antibiotics, at first encounter.  Time to first S.aureus and P.aeruginosa detection in the 
UK/US cohorts were compared using a Cox proportional hazards model.  A UK-based analysis 
compared the same for those receiving flucloxacillin with those who received no prophylaxis. 
We included the following covariates: sex, age at registry entry, Dornase alfa use, genotype 
and center size.  
Main results 
The primary analysis consisted 1074 UK and 3677 US children. The risk of first detection was 
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greater in US compared to UK for S.aureus (hazard ratio (HR) 5.79; 95% CI: 4.85, 6.90; p<0.001) 
and P.aeruginosa (HR 1.92; 95% CI: 1.65, 2.24; p<0.001).  The UK analysis compared 278 
children receiving flucloxacillin and 306 receiving no prophylaxis. Flucloxacillin was not 
associated with a reduced risk of S.aureus (HR 1.22; 95% CI: 0.74, 2.0; p=0.43), but was 
associated with an increased risk of P.aeruginosa (HR 2.53; 95% CI: 1.71, 3.74; p<0.001) 
detection. None of the covariates significantly affected the risk estimate in either analysis.  
Conclusions 
Risk of first detection of S.aureus and P.aeruginosa was greater in US compared to UK. In the 
UK, the risk of first P.aeruginosa detection was increased among those receiving flucloxacillin 
compared to those who received no prophylaxis. These observational findings should be 
examined in randomised controlled trials. 
Abstract word count: 324 
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INTRODUCTION 
The hallmark of cystic fibrosis (CF) lung disease is increased susceptibility to chronic 
endobronchial infection.(1) Staphylococcus aureus is the most common respiratory pathogen 
in infants and young children with CF,(2) the detection of which is independently associated 
with lower respiratory tract inflammation.(3)  In the UK prophylactic antibiotics are 
administered with the aim of preventing infection with S. aureus.(4)  U.S. registry data, for 
young children with CF, show a prevalence of 60-70% for S. aureus, and a prevalence of around 
20% for P. aeruginosa.(5) In the U.K., comparable registry figures are 14% for S. aureus and 
21% for P. aeruginosa.(6) 
Internationally, the issue of antibiotic prophylaxis for S. aureus is controversial.(7-9)  The 
evidence supporting the use of anti-staphylococcal therapy is summarized in a Cochrane 
review which concluded that, while prophylaxis appeared to reduce the detection of S. aureus, 
no effect was observed on clinical status and the significance of the increased rate of P. 
aeruginosa detection seen in one trial was uncertain.(10)  Nevertheless, the Cochrane 
review(10) and the UK CF Trust working group(4) recommend the use of S. aureus prophylaxis 
until 3 years of age.  In contrast, concerns regarding the possibility of the emergence of P. 
aeruginosa and uncertainty regarding clinical benefit prompted the US Cystic Fibrosis 
Foundation to recommend against prophylaxis.(9) As a result, S. aureus prophylaxis is in 
general not practiced in the US.  
Our objective was to test the hypothesis that anti-staphylococcal antibiotic prophylaxis 
confers a positive microbiologic outcome for children with CF (prolongation of the time to first 
S. aureus detection), without an increase in microbiologic complications (reduced time to first 
detection of P. aeruginosa). 
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 METHODS 
We aimed to identify the first occasion when S. aureus, P. aeruginosa and MRSA was detected 
for each child and describe the time to first infection for each cohort.   
The Registries 
We retrieved data for the years 2000-2009 inclusive from the UK Cystic Fibrosis Trust Registry 
and US Cystic Fibrosis Foundation National Patient Registry.  In the US Registry, data from each 
clinical encounter are entered into the Registry (Figure S1).  The UK Registry however 
documents annual data.  As a result clinical encounters of the year are reviewed and 
summarised at the annual review, traditionally in the child’s birth month. It is the date of the 
annual review and the detail of the annual summary that is recorded on the Registry.   
In order to make the US Registry data as equivalent as possible to the UK for the primary 
(UK/US) analysis, we annualised the US data by condensing the encounter-level data to a 
single record per calendar year.  This was achieved by identifying the encounter nearest to the 
child’s birthday.  For the variables of interest, this entry summarised the activity in the 
previous year.  This is described in more detail in the online supplement. 
Study population 
Our cohorts comprised children with a diagnosis of CF enrolled in the registries before the age 
of 1500 days (approximately 4 years).  We chose 4 years to maximize the time for children to 
have a bacterium isolated from their respiratory samples, 1 year beyond the time period that 
UK guidelines recommend anti-staphylococcal antibiotic prophylaxis be used.  Routine 
practice in the UK is for children to have a respiratory sample taken at each clinical encounter 
(4-6 times a year) and in the US samples taken quarterly.  We excluded children who isolated 
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S. aureus (methicillin-susceptible or –resistant) and P. aeruginosa at first registry encounter.  
We excluded those receiving inhaled tobramycin or colistin at first registry encounter, as these 
children were likely to have already acquired P. aeruginosa.  We also excluded those children 
with only one registry entry.  
We unexpectedly identified a cohort of children in the UK that were documented as not 
receiving antibiotic prophylaxis.  As a result we were able to undertake two analyses.   
Analyses 
The primary analysis evaluated the time to first detection of infection in children with CF in 
the UK (S. aureus prophylaxis recommended until three years of age) and US (S. aureus 
prophylaxis not practiced in the first three years of life).  We were also able to undertake a 
secondary analysis evaluating time to first infection with S. aureus and P. aeruginosa among 
children in the UK recorded as receiving flucloxacillin prophylaxis vs. no prophylaxis. There 
were a number of children in the UK registry recorded as receiving a number of different oral 
antibiotics given over a prolonged time, making it unclear whether these were prophylactic 
antibiotics. We therefore limited the analysis of prophylactic antibiotics in the UK to children 
in whom the same chronic antibiotic - or no antibiotic - was recorded over two successive 
years.  Due to the small number of children who consistently received an antibiotic other than 
flucloxacillin these children were also excluded.  Thus the final comparison was between those 
who received flucloxacillin or no prophylaxis. 
Analytic methods 
For the survival analyses, failure time was defined as time to first detection of P. aeruginosa 
or S. aureus, respectively. Children not acquiring these organisms during follow up were 
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censored at the last data entry prior to the age of 1500 days, or end of the study (31 December 
2009) for those not reaching the age of 1500 days. We determined if country (US/UK) or the 
use of antibiotic prophylaxis (for the UK-based analysis) was associated with the time to first 
detection using a Cox proportional hazards regression model, after confirming the 
proportional hazards assumptions were not violated based on Schoenfeld residuals. Potential 
confounding factors (gender, age at registry entry, Dornase alfa use, genotype (homozygous 
Phe508del, other) and center size) were included if they individually resulted in a 10% or 
greater change to the estimate.(11)  Kaplan-Meier plots were constructed to illustrate the 
survival analysis.  
We undertook several sensitivity analyses in order to detect any effects of decisions made in 
the protocol upon the final results, these are described in the online supplement. The STROBE 
guidelines were used for reporting(12). All data was analysed with Stata SE12 (College Station, 
Texas, USA).  The study received no specific funding.  MH was funded by a Wellcome Trust 
Research Training Fellowship (WT092295MA) and latterly a NIHR Academic Clinical 
Lectureship. 
The protocol is available online as detailed in the online supplement. 
RESULTS 
Primary analysis cohort derivation and characteristics  
For the years 2000-2009, there were 2325 individuals in the UK registry and 11002 individuals 
in the US registry younger than 1500 days at registry entry. After excluding children who were 
receiving inhaled tobramycin or colistin at the first annualised registry entry (n=474 in the UK, 
n=1589 in the US) those in whom S. aureus or P. aeruginosa was detected at their first entry 
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(n=272 in the UK, n=5104 in the US) and those with only one registry entry (n=505 in the UK, 
n=745 in the US), the final study cohort consisted of 1074 UK children and 3564 US children 
(Figure 1). As shown in Table 1, the characteristics of children included in and excluded from 
the final cohorts as well as those of the UK and US cohorts were similar with the exception of 
a much higher prevalence of Dornase alfa use in the US. 
Primary analysis – comparison of detection of bacteria between UK and US 
The risk of first detection of S. aureus (MSSA) was significantly greater in the US cohort than 
the UK cohort (hazard ratio (HR) 5.79; 95% CI 4.86, 6.90, p<0.001)(Figure 2). Similarly, the risks 
of first detection of P. aeruginosa (HR 1.92; 95% CI 1.65, 2.23, p<0.001)(Figure 2) and MRSA 
(HR 5.66; 95% CI 3.35, 9.57, p<0.001)(Figure 2) were significantly greater in the US than the 
UK.  None of the model estimates was changed by 10% or more following inclusion of sex, CF 
genotype, Dornase alfa or age at registry entry as covariates. 
In order to determine if the method of cohort selection exerted a significant effect upon the 
results, a sensitivity analysis was conducted which included all children younger than 1500 
days.  Another sensitivity analysis determined if the direction of effect changed over the time 
period of the study by comparing the periods 2000-2004 and 2005-2009.  For both sensitivity 
analyses the estimates of the hazard ratios were similar to the original analyses (see online 
supplement). 
Secondary analysis– UK based comparison of flucloxacillin versus no prophylaxis 
Of all the 2325 children in the UK registry, 1696 children were documented to have received 
a consistent regimen (either a consistent antibiotic class or no chronic antibiotics).  Of the 
1074 children included the UK cohort of the UK/US analysis, 470 were excluded from this 
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secondary analysis due to inconsistent antibiotic prophylaxis (n=442) or consistent use of 
prophylaxis with an antibiotic other than flucloxacillin (n=28). We included 604 children, with 
2 or more years of data, in the analysis, of whom 326 received flucloxacillin and 278 received 
no prophylaxis (Figure 1).   
Distribution of prophylactic antibiotic use by center was examined and (Figure S2) 
demonstrated a spectrum of use across centers.  The characteristics of the UK cohort, 
comparing those included to those excluded from analysis, is shown in Table 2. 
Time to first detection of S. aureus and P. aeruginosa 
Sixty-four children experienced their first S. aureus culture detection during 1023.9 person 
years at risk. Flucloxacillin use was not associated with risk of first detection of S. aureus (HR 
1.22; 95% CI 0.74, 2.0, p=0.43).  One hundred and thirteen children had their first P. 
aeruginosa detection during 970.7 person years at risk, with those receiving flucloxacillin 
having a significantly increased hazard (HR 2.53; 95% CI 1.71, 3.74, p<0.001) compared to 
those receiving no prophylaxis. There was no association detected between prophylaxis use 
and detection of MRSA (HR 1.57; 95% CI 0.1, 25.2, p=0.75). Inclusion of sex, age at entry to 
the registry, Dornase alfa use, genotype and center size as covariates did not significantly 
affect the risk estimates for any of the models.  
Sensitivity analysis 
To determine if the results of the UK-based analysis were similar in those with the most 
complete data, in those children up until the age of 3 (as per UK guidance regarding duration 
of prophylaxis) and in order to consider if time trends exerted an effect over the duration of 
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the study, further sensitivity analyses were conducted, the results of which were not 
significantly different than the original results (presented in the online supplement). 
 
DISCUSSION 
This study is the first observational study to examine the effect of S. aureus antibiotic 
prophylaxis in infants with CF on microbiologic outcomes using ‘real-world’ data and furthers 
the debate regarding its risks and benefits.  In this retrospective study describing the first 
detection of S. aureus and P. aeruginosa in the UK and US we found that the risk of first 
detection of both organisms is significantly increased in the US compared to the UK.  
Unexpectedly, we discovered a cohort of children in the UK that were not documented to be 
receiving anti-staphylococcal antibiotic prophylaxis.  We therefore undertook an analysis of a 
cohort of children in the UK who either consistently received flucloxacillin or received no 
prophylaxis.  We found that flucloxacillin use does not appear to be associated with a reduced 
risk of first detection of S. aureus.  However flucloxacillin use does appear to be associated 
with an increased risk of first detection of P. aeruginosa.   
Our findings differ from the conclusions of a Cochrane review which found that anti-
staphylococcal prophylaxis resulted in a reduction in the proportion of children isolating S. 
aureus.(10) The Cochrane review considers only randomised controlled trials, which may in 
part explain this difference. Furthermore, only two of the included studies involved 
flucloxacillin and both of these were open label studies comparing continuous flucloxacillin 
prophylaxis with ‘as-required’ arms instead of placebo.  The only double-blind randomised 
trial of antibiotic prophylaxis used cephalexin and observed a delay in detection of S. aureus 
but an increase in detection of P. aeruginosa, (13), an observation that is consistent with our 
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data. An Australian observational study utilizing bronchoalveolar lavage-based microbiological 
sampling found that co-amoxiclav (amoxillin-clavulanate) antibiotic prophylaxis use was not 
associated with either detection of P. aeruginosa or S. aureus(14), though there was a non-
significant excess of P. aeruginosa isolates in the prophylaxis group.  It is possible that the 
Australian study did not have sufficient power to detect a significant difference.  
There is a contradiction that lies within these data – in the US (where antibiotic prophylaxis is 
not administered) the risk of first detection of P. aeruginosa is greater than in the UK.  Yet 
when examining the UK data we observe that those administered prophylaxis have a reduced 
time to first P. aeruginosa infection compared with those not given prophylaxis.  It is likely 
that the observed differences in risk of detection of P. aeruginosa, S. aureus and MRSA 
between the US and UK are due to differences in ecological conditions in the two countries 
(e.g, very different rates of microbial colonization in the general and CF populations and major 
differences in the healthcare systems), rather than any association with staphylococcal 
prophylaxis. In fact, the finding of a significantly earlier age of first detection of S. aureus in 
the US compared to the UK is not surprising given the previously identified 3–fold greater 
annual prevalence of MSSA and an 8-fold greater annual prevalence of MRSA in US CF centers 
compared to the UK.(15) The nasopharyngeal carriage of S. aureus among healthy children in 
the UK is unknown whereas such carriage has been reported to be as high as 48% in the US(16) 
and 36% in the Netherlands.(17)  
It is known that more sampling opportunities provide a greater chance of isolating an 
organism should it be present. The European Cystic Fibrosis Society and UK CF Trust standards 
of care suggest that patients should be seen every 1-3 months,(7, 8) however while this may 
be commonplace for young children, anecdotally the true frequency of visits is likely to lie at 
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the upper end of the range.  In the US dataset, where data from every clinic visit are 
documented, the median gap between visits for children under 4 years (1500 days) old was 
53 days (IQR 28, 89 days). The more frequent sampling in the US could have contributed to 
the observed higher detection rates, but again are unlikely to explain the entire effect. 
Due to the differences in the way data are recorded in the two registries, namely that the US 
data consists of encounter-based data whereas the UK data consists of an annual summary of 
the previous year, an immortal time bias (a period of time where it is not possible to detect a 
bacterial isolate) could exist. We annualised the US data to minimize this source of bias.  The 
size of the observed effect, in combination with the significant differences between 
prevalence of infection in the two countries, suggest that immortal time bias is unlikely to 
account for all the observed differences.  
One potential explanation for the increased risk of P. aeruginosa infection among those 
receiving flucloxacillin in the UK analysis is reverse causation – that patients were actually 
receiving treatment of persistent symptoms rather than prophylaxis.  If that were the case, 
these individuals would have been sicker, with more structural lung disease, and so 
consequently at increased risk of P. aeruginosa infection. The fact that S. aureus detection 
rates were similar between these two groups argues against reverse causation to some 
degree.  
In the earlier years of the UK Registry a substantial proportion of individuals had incomplete 
data (29% in 2001). However the proportion with incomplete data has steadily decreased over 
time (11% incomplete in 2014).  Our sensitivity analyses suggest that changes in the 
completeness of data did not have a significant effect upon our findings.  The time period of 
this study (2000 – 2009) includes a period when newborn screening was not widely 
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implemented in either the UK or the US. Furthermore, microbiological laboratory techniques 
may have changed. These factors may limit the generalisability of our findings.  
The polymicrobial nature of CF lung infection is increasingly appreciated.(18) Those with good 
lung function host greater lung microbial diversity compared to their counterparts with poorer 
lung function or who experience frequent exacerbations.(19, 20)  The effect of prophylactic 
antibiotics upon this complex ecosystem is unknown.  This question is particularly significant 
given that the effect of intravenous antibiotics upon the microbiome appears to be limited in 
terms of quantitative microbiology, but significant in terms of bacterial diversity.(20) (21) It 
may be that chronic exposure to prophylactic antibiotics disrupts the fecal and/or respiratory 
microbiome, providing a favourable ecosystem for opportunistic bacteria like P. aeruginosa. 
The large numbers of children from the two countries providing data to the registries is a 
significant strength. One important limitation of our study is that it relies on oropharyngeal 
and cough swabs, which are known to have relatively low sensitivity and specificity for lower 
airway infection, (22) (23) particularly as S. aureus colonisation of the upper airways of healthy 
children is common.(16) Thus, our results describing upper airway cultures may not be 
generalizable to lower airway infection.  We also do not have adherence data in either registry.   
Given these limitations, these data should be interpreted with caution.  Nevertheless, these 
results will be concerning to those who endeavour to postpone the age at which infection with 
either S. aureus or P. aeruginosa is first acquired.  Infection with S. aureus in the 1960s and 
1970s had a devastating effect in young children. However the improved management, 
standards of living, nutrition and subsequent survival of children with CF is such that the 
spectrum of disease seen in this earlier era does not reflect the current situation.(24)  This 
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might mean that the balance of risks and benefits of staphylococcal prophylaxis has changed 
- the tenet of ‘first do no harm’ appears to be apt.   
A randomised controlled trial of antistaphylococcal prophylaxis in the UK has commenced 
(http://www.nets.nihr.ac.uk/projects/hta/142223) which will address the biases of the 
previous studies.  It will also be important in the future to determine the effect of such 
antibiotic administration upon the flora of the lungs of young children with CF in order to 
explain the findings of the RCT in microbiological terms. 
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Figure legends 
Figure 1: Illustration of derivation of cohorts for a) UK vs. US and b) UK flucloxacillin vs. no 
prophylaxis comparisons. 
Figure 2:  Kaplan-Meier plot of time to first acquisition of S. aureus, P. aeruginosa and MRSA 
in UK and US truncated at 3 years 
Figure 3:  Kaplan Meier plot of time to first acquisition of S. aureus and P. aeruginosa by 
prophylaxis use in UK truncated at 3 years 
 
Figure S1: Illustration of clinical encounters and data entry.  Clinical encounters (gold dots) 
are summarised at the annual review (black dot) and entered onto the Registry.  The first 
bacterial detection (hollow diamond) is entered onto the Registry at the annual review 
(black dot and solid diamond).  Child D is excluded from the study as they were receiving 
inhaled colistin suggesting a previous infection.  Child E remains infection-free and is 
censored at the end of the study period as they do not reach the exit age of just over 4 years 
(1500 days).  
Figure S2: Distribution of antibiotic prophylaxis use in UK by center 
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Tables 
Table 1: Baseline characteristics of UK and US registries before and after cohort selection 
included in UK/US analysis (%, IQR) for children up to just over 4 years (1500 days). 
 
All children aged younger than 1500 
days at registry entry 
 (n (%) or median (IQR)) 
Included in final cohort  
(n (%) or median (IQR)) 
UK US UK US 
n 2325 11002 1074 3564 
Male 1169 (50.3%) 5512 (50.1) 562 (52.3%) 1806 (49.3%) 
Female 1156 (49.7%) 5490 (49.9) 512 (47.7%) 1758 (50.7%)  
Age at entry 
(days) 
475 (351, 975) 352 (319, 717) 381 (225, 691) 354 (322, 718) 
Diagnosed by 
screening/PNS 
815 (35.1%) 3550 (32.3%) 417 (38.8%) 955 (26.8%) 
BMI z-score 0.4 (-0.3, 1.1) 0.3 (-0.5, 0.9) 0.36 (-0.5, 1.1) 0.26 (-0.5, 1.0) 
Dornase alfa 
(ever in first 
1500 days) 
158 (6.8%) 4157 (37.8%) 71 (6.6%) 1171 (32.9%) 
Homozygous 
Phe508del * 
1271 (54.7%) 5094 (46.3%) 588 (54.8%) 1665(46.7%) 
*percentage of total including those with missing or unknown genotype data.  After 
annualisation of US data.  PNS – prenatal screening. 
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Table 2:  Baseline characteristics of children included in and excluded from UK comparison 
(N (%) or median (IQR)) 
 
  
No 
prophylaxis 
Flucloxacillin 
prophylaxis 
Between 
included 
groups, 
p= 
 Excluded 
Included 
vs. 
excluded, 
p= 
 
n 278 326 -  1721 - 
Male 159 (57.0) 167 (50.9) 0.16  843 (49.0) 0.04 
Age at entry, 
days  
410 (277, 
773) 
383.5 (270, 
699) 
0.06  547 (359, 1085) <0.001 
BMI z-score  
0.46 (-0.47, 
1.20) 
0.37 (-0.46, 
1.08) 
0.47  0.44 (-0.29, 1.15) 0.52 
Dornase alfa 
(ever in first 
1500 days ) 
18 (6.5%) 21 (6.4%) 1.0  119 (6.9%) 0.78 
dF508/dF508* 151 (54.3%) 179 (54.9%) 0.94  941 (54.7%) 1.0 
*percentage of total including those with missing or unknown genotype data.   
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Figure 1: Illustration of derivation of cohorts for a) UK vs. US and b) UK flucloxacillin vs. no 
prophylaxis comparisons.   
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Kaplan-Meier plot of time to first acquisition of S. aureus, P. aeruginosa and MRSA in UK and 
US truncated at 3 years 
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Kaplan Meier plot of time to first acquisition of S. aureus and P. aeruginosa by prophylaxis 
use in UK truncated at 3 years 
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ONLINE DATA SUPPLEMENT 
Early respiratory bacterial detection in young children with cystic fibrosis in the US and UK 
and association with anti-staphylococcal antibiotic prophylaxis use in the UK 
Matthew N Hurley, Andrew Fogarty, Tricia M McKeever, Chris CH Goss, Margaret Rosenfeld, 
Alan R Smyth 
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Further methods 
Outcome and annualisation 
The US Registry details encounter-based data and so data from each clinical encounter is 
documented (gold dots on the illustration; Figure S1).  The UK Registry however documents 
annual data.  As a result clinical encounters of the year are reviewed and summarised at the 
annual review (black dots), traditionally in the child’s birth month. It is the date of the annual 
review that is recorded on the Registry.   
As in the illustration below (Figure S1), in the UK Registry encounters (gold dots) do not appear 
on the Registry, instead they are summarised annually at the annual assessment (black dots).  
For example, child A & B were identified through newborn screening and diagnosed soon 
after.  They were present throughout the study period.  Child A had a positive isolate at 3 years 
3 months of age (hollow red diamond).  This was captured at the annual assessment and 
recorded on the Registry (black dot at 1460 days).  Child A exits the study at that point.  The 
time of ‘failure’ for the time-to-event analysis is the date of the annual assessment (solid red 
diamond).   
Child B had a positive isolate at 1 year 5 months of age (hollow red diamond) and this was 
captured at the following annual assessment and recorded on the Registry (black dot at 720 
days). The time of ‘failure’ for the time-to-event analysis is the date of the annual assessment 
(solid red diamond).   
Child C enters the study at the age of 18 months as they were born before commencement of 
the study period (left censoring).  Child C had a positive isolate at 3 years 3 months of age 
(hollow red diamond).  This was summarised at the following annual assessment and recorded 
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on the Registry (black dot at 1460 days). The time of ‘failure’ for the time-to-event analysis is 
the date of the annual assessment (solid red diamond).  Child D’s data are also left censored 
however there is an indication that previous infection may have been encountered as the child 
was receiving inhaled colistin at first entry, and so was excluded from the study. 
Child E does not have a positive isolate however does not reach their 4th birthday as the study 
period ends and so their entry is right censored. 
In contrast, as the US data documents each encounter the data is more continuous and so 
there are Registry data entries for each dot.  In order to replicate the structure of the UK 
Registry, the US data were ‘annualised’.  This was achieved by identifying the encounter 
nearest to the child’s birthday.  For the variables of interest, this entry represented the activity 
in the previous year.  Just as in the UK Registry, if a child encountered an isolate in the previous 
year, as is the case with Child B at 18 months, this is recorded at the birthday encounter (at 
720 days). 
Culture methods 
Almost all respiratory cultures were obtained from cough swabs or oropharyngeal swabs, as 
young children can rarely expectorate and bronchoalveolar lavage is not routinely performed 
in the US or UK. 
We undertook several sensitivity analyses in order to detect any effect of decisions made in 
the protocol upon the final results.  First, for the US/UK comparison, we repeated it for all 
children <1500 days at study entry regardless of whether they met the exclusion criteria. To 
evaluate the effect of incomplete data collection in the early years of the UK Registry, we 
conducted a sensitivity analysis for both the UK/US comparison and the within-UK 
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comparison comparing the time periods 2000-04 and 2005-09 (table 3). For the UK 
evaluation of prophylactic antibiotics, we repeated the analysis including the children 
receiving an inconsistent antibiotic regimen in the prophylaxis group.  Further sensitivity 
analyses were conducted for the UK-based analysis limiting the cohort to those with three or 
more consistent visits with a respiratory culture result recorded and those aged younger 
than 3 years. In the sensitivity analyses, characteristics of the included and excluded samples 
were compared using Pearson chi2 test, Fisher exact and the Mann-Whitney U test as 
appropriate.   
Protocol 
The study protocol is available at http://eprints.nottingham.ac.uk/37205/ 
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Further results 
UK vs. US analysis 
Sensitivity analysis 
In order to determine if the selection of the included cohorts had a significant effect on the 
results, the analysis was repeated using the entire unselected cohort of children <1500 days 
of age (2325 UK children and 11002 US children). The risk of first acquisition of S. aureus for 
the US vs. the UK was HR 5.47; 95% CI 4.70, 6.38, p<0.001; P. aeruginosa, HR 1.82; 95% CI 
1.60, 2.07, p<0.001; and MRSA HR 6.67; 95% CI 4.27, 10.41, p<0.001, similar to the primary 
analysis.  A second sensitivity analysis investigated whether there were significant time trends 
between the beginning and end of the period demonstrating that the same results held (table 
E1).  In this analysis we saw the same trends as observed in the original analysis, albeit with 
larger confidence intervals. 
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UK (Flucloxacillin vs. No prophylaxis) analysis 
Centre-based analysis of variation in practice 
Figure S2 illustrates the variation in practice across individual centres. 
Sensitivity analysis 
To determine if the results of the UK-based analysis held in those with most complete data 
(those with three or more consistent visits with a respiratory culture recorded) we conducted 
a sensitivity analysis in this group (n=288).  There was still no statistically significant difference 
in the risk of first acquisition of S. aureus associated with flucloxacillin use (HR 1.27; 95% CI 
0.71, 7.19, p=0.429), while the finding of a statistically significant increased risk of first 
acquisition of P. aeruginosa persisted (HR 2.17; 95% CI 1.39, 3.38, p=0.001). 
In a second sensitivity analysis, considering time at risk only up to the age of 3 years (n=446), 
the risk of first acquisition of S. aureus is also not statistically significantly different between 
the two groups (HR 1.55; 95% CI 0.72, 3.33, p=0.26) while the finding of a statistically 
significantly increased risk of first acquisition of P. aeruginosa in the flucloxacillin group 
persisted (HR 2.94; 95% CI 1.78, 4.85, p<0.001).  A third sensitivity analysis investigated 
whether there were significant time trends between the beginning and end of the period 
demonstrating that the same results held, although the increased risk of P.aeruginosa in the 
later period was no longer significant (table E2). 
We detected significant differences in the UK/US analysis and in the P. aeruginosa analysis of 
the UK data.  The post-hoc power of the UK flucloxacillin/none analysis (S. aureus) comparison 
(for which there was no difference) is 67% based on an estimated power for two-sample 
comparison of survivor functions - Log-rank test, Freedman method. 
  30 
 
Table E2: Sensitivity analyses of risk of first acquisition by epoch   
 
Supplemental Figure Legends:  
  
Figure S1: Illustration of clinical encounters and data entry.  Clinical encounters (gold dots) are 
summarised at the annual review (black dot) and entered onto the Registry.  The first bacterial 
detection (hollow diamond) is entered onto the Registry at the annual review (black dot and 
solid diamond).  Child D is excluded from the study as they were receiving inhaled colistin 
suggesting a previous infection.  Child E remains infection-free and is censored at the end of 
the study period as they do not reach the exit age of just over 4 years (1500 days).   
  
Figure S2: Distribution of antibiotic prophylaxis use in UK by center 
 
 
 
 
UK/US analysis 
Failures 
(n) 
All years 
(HR, 95% CI) 
Failures 
(n) 
2000-2004 
(HR, 95% CI) 
Failures 
(n) 
2005-2009 
(HR, 95% CI) 
S. aureus 2232 
5.79  
(4.85, 6.90) 
1561 
4.73  
(3.90, 5.75) 
671 
11.03  
(7.2, 16.89) 
P. aeruginosa 1495 
1.92  
(1.65, 2.24) 
1088 
1.72  
(1.45, 2.04) 
407 
2.80  
(2.02, 3.87) 
Table E1: Sensitivity analyses of risk of first acquisition by epoch   
 
 
Flucloxacillin / 
No prophylaxis 
Failures 
(n) 
All years 
(HR, 95% CI) 
Failures 
(n) 
2000-2004 
(HR, 95% CI) 
Failures 
(n) 
2005-2009 
(HR, 95% CI) 
S. aureus 64 
1.22  
(0.74, 2.0) 
54 
1.29  
(0.76, 2.21) 
10 
1.16  
(0.30, 4.48) 
P.aeruginosa 113 
2.53  
(1.71, 3.74) 
91 
2.73  
(1.78, 4.18) 
22 
2.03  
(0.73, 5.68) 
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  Illustration of clinical encounters and data entry.  Clinical encounters (gold dots) are 
summarised at the annual review (black dot) and entered onto the Registry.  The first 
bacterial detection (hollow diamond) is entered onto the Registry at the annual review 
(black dot and solid diamond).  Child D is excluded from the study as they were receiving 
inhaled colistin suggesting a previous infection.  Child E remains infection-free and is 
censored at the end of the study period as they do not reach the exit age of just over 4 years 
(1500 days).  
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Distribution of antibiotic prophylaxis use in UK by center 
